Maquetaciã³n 1

Total Page:16

File Type:pdf, Size:1020Kb

Maquetaciã³n 1 EMERGING DRUGS CLINICAL COMMITTEE REPORTS GOBIERNO MINISTERIO DE ESPAÑA DE SANIDAD, POLÍTICA SOCIAL E IGUALDAD GENERAL SECRESECRETARIATTTAARIAATT FOR SOCIAL POLICY AND CONSUMER GOVERNMENTGOVERRNMENT MINISTRYMINISTRRYY PPROTECTIONROOTTECTION OF SPAINSPPAAIN OF HEALTH,HEALLTTH, SOCIAL POLICYY AND EQUALITYEQUALITY GGOVERNMENTOVERNMENT DELEGDELEGATIONAATTION FOR THE NATIONALNAATIONALTIONAL PLAN ON DRUGSDRUGS EDITORIAL PANEL Clinical Committee of the Government Delegation for the National Plan on Drugs: Manuel Sanchís Fortea Julia González Alonso Elena Álvarez Martín Carlos Álvarez Vara Julio Bobes García Begoña Brime Beteta Exuperio Díez Tejedor Magí Farré Albaladejo Juan Flores Cid Aurelio Luna Maldonado Amparo Sánchez Máñez Rosario Sendino Gómez Marta Torrens Melich ACKNOWLEDGEMENTS The Clinical Committee of the Government Delegation for the National Plan on Drugs would like to acknowledge the contribution and documentary and technical support of the following people: Noelia Llorens Aleixandre Mercedes Rubio Ferreiro Francisco Ràbago Lucerga MINISTRY OF HEALTH, SOCIAL POLICY AND EQUALITY Published and distributed by: © MINISTRY OF HEALTH, SOCIAL POLICY AND PUBLISHING UNIT Paseo del Prado, 18. 28014 Madrid © GENERAL SECRETARIAT FOR SOCIAL POLICY AND CONSUMER PROTECTION GOVERNMENT DELEGATION FOR THE NATIONAL PLAN ON DRUGS ONLINE NIPO: 860-11-054-9 PAPER NIPO: 860-11-054-9 ISBN: 978-84-920522-8-8 Legal deposit: M-38788-2011 Layout: ADVANTIA COMUNICACIÓN GRÁFICA, S.A. Printed by: ADVANTIA COMUNICACIÓN GRÁFICA, S.A. Website: http://www.pnsd.mspsi.es Clinical Committee of the Government Delegation for the National Plan on Drugs Chair Mrs. Nuria Espí de Navas Government Delegate for the National Plan on Drugs Members Mr. Manuel Sanchís Fortea Mrs. Julia González Alonso Mrs. Elena Álvarez Martín Mr. Carlos Álvarez Vara Mr. Julio Bobes García Mrs. Begoña Brime Beteta Mr. Exuperio Díez Tejedor Mrs. Magí Farré Albaladejo Mr. Juan Flores Cid Mr. Aurelio Luna Maldonado Mrs. Amparo Sánchez Máñez Mrs. Rosario Sendino Gómez Mrs. Marta Torrens Melich Preface This sixth report by the Clinical Committee of the Government Delegation for the National Plan on Drugs analyses the wide range of effects of the so-called “emerging drugs”. This term would include other expressions such as “synthetic drugs”, “designer drugs” or “recreational drugs”, which are very commonly used but whose meaning may not be sufficiently clear and accurate. Emerging drugs are illegaly synthetized substances intended to cause, by means of some variations in the chemical structure, similar or even higher effects than classical drugs as well as to avoid the normative control that the latter are subject to. These drugs appear, reappear or emerge in the market and the mass media (which explains the term used in this monograph) in a recurrent manner. Since the analysis and review of drugs policies of the last few years, and more specifically in Spain since the National Plan on Drugs came into effect in 1985, the social perception of the issue of drug use and drug addiction has changed dramatically. The world of drug abuse and psychoactive substances with recreational purposes is constantly changing. Therefore it is vital for all those professionals involved in their clinical-therapeutic treatment and prevention to know the current trends of use, the types of substances used or the new use and toxicity patterns. Their use and abuse are linked to a festive atmosphere, mostly on weekends, among teenagers and young people, who are familiar with their stimulating effects that help relate to others, but who, most of the times, ignore their harmful effects to their health. All this is frequently exacerbated by the use of alcohol and the common fraud regarding the composition of these “pills”, which are adulterated with all kind of psychoactive or solvent products. There is an increasingly high number of these substances. The European Union informed of the emegence of around 40 new substances in 2010, including plants and fungus, vitamines, minerals, legal drugs or their copies and unauthorized chemical substances with various ways of marketing and use (pills, plant extracts, fresh or dry fungus, soaps, vegetable fertilizers, infusions, inhaling products, etc.). Moreover, their spreading has been significantly increased by the Internet, which contains a huge amount of information about their procurement, synthesis, identificacion, use, effects and marketing of this type of substances. It is pseudo-scientific information not verified or contrasted 7 frequently used to justify the promotion of the use of these substances on many websites. This is why the new trends of use and development may escape from the control and follow-up mechanisms of the State. The virtual and global nature of the Internet, the difficulty in applying legal restrictive measures and their relative anonymity and rapidity foster their trade and distribution. The Clinical Committee of the Government Delegation for the National Plan on Drugs provides professionals with a practical monography condensing the current knowledge on emerging drugs and their effects on people’s health and welfare. This volume contains updated information on the current situation of the use of this type of substances in our country and reviews some legal and social aspects related to it. Its accessible language and clear presentation make the reading and understanding easier to all those interested in this subject. I would like to express my gratitude to all the members of the Clinical Committee for the work done and encourage them to keep on this task. Leire Pajín Iraola Minister of Health, Social Policy and Equality 8 Contents I. Introduction ......................................................................... 13 II. General concepts ................................................................. 17 2.1. Definitions ................................................................... 17 2.2. Classification ............................................................... 19 2.3. Ways of presentation. Ways of use. Ways of administration ............................................... 23 2.4. Early Warning System (EWS) ..................................... 23 III. Current situation ................................................................. 31 3.1. International situation: prevalence of use, trafficking and seizures ................................................................. 31 3.1.1. Situation around the world ............................. 31 3.1.2. Situation in Europe ......................................... 37 3.2. Current situation in Spain: prevalence of use, trafficking and seizures ................................................ 45 IV. Amphetamines ..................................................................... 69 4.1. Composition ............................................................... 69 4.2. Nomenclature ............................................................. 73 4.3. Ways of administration and use ................................. 73 4.4. Pharmacology ............................................................. 75 4.5. Clinical signs ............................................................... 79 4.6. Intoxication, addiction and withdrawal symptoms ... 82 4.7. Therapeutic intervention ............................................ 83 9 4.8. Mephedrone and other synthetic cathinones ............ 87 4.9. Bromo-dragonfly ......................................................... 89 V. Piperazines ........................................................................... 93 5.1. Classification ............................................................... 93 5.2. Ways of administration and use ................................. 94 5.3. Pharmacology ............................................................. 95 5.4. Clinical signs ............................................................... 96 5.5. Therapeutic intervention ............................................ 98 VI. Pyrrolidinophenones .......................................................... 99 VII. Ketamine ............................................................................... 101 7.1. Nomenclature ............................................................. 101 7.2. Ways of administration ............................................... 102 7.3. Pharmacology ............................................................. 102 7.4. Clinical signs ............................................................... 106 7.5. Therapeutic intervention ............................................ 110 7.6. Legal situation ............................................................. 110 VIII. Spice drugs ........................................................................... 113 8.1. Nomenclature ............................................................. 113 8.2. Composition ............................................................... 114 8.3. Ways of administration. Ways of use ......................... 115 8.4. Pharmacology ............................................................. 116 8.5. Clinical signs ............................................................... 117 10 8.6. Therapeutic intervention ............................................ 118 8.7. Legal situation ............................................................. 118 IX. GHB/GBL .............................................................................. 121 9.1. Composition ..............................................................
Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • KHAT Latest Revision: June 11, 2005
    KHAT Latest Revision: June 11, 2005 O CH3 NH2 Cathinone OH CH3 NH2 Cathine N CH3 H3C N 3,6-dimethyl-2,5-diphenylpyrazine (dimer of Cathinone) 1. SYNONYMS CFR: Cathinone Cathine CAS #: Cathinone Hydrochloride: 71031-15-7 Cathine Hydrochloride: 2153-98-2 Cathine Base: 492-39-7 Other Names: Catha edulis Kat Mutsawhari Mutsawari Mdimamadzi Musitate Mirungi Miraa Ol meraa Tumayot Liruti Ikwa Arabian Tea 2. CHEMICAL AND PHYSICAL DATA Khat is used as a stimulant or as a medicine in parts of Africa and the Arabian Peninsula. The plant is thought to have been in cultivation before the coffee plant; historical references date the use of the plant to the fourteenth century. Peter Forsskal, a physician and botanist, collected khat specimens in an expedition organized by the King of Denmark in the eighteenth century. Forsskal assigned the name Catha edulis to the plant. The effects produced by the drug include excitation, hypersensitivity, anorexia, insomnia, euphoria, increased respiration, and hyperthermia. These effects closely parallel the effects of d-amphetamine. Khat is a bush or tree that grows naturally in the humid mountainous regions (elevations of 5000 to 6500 feet) of East and South Africa. The trees can grow naturally to over 60 ft; however, cultivated khat trees are pruned and their height to kept to approximately 16 feet. Khat also grows to a height of 3 feet as a small bush in arid regions. Like opium, the alkaloid content of khat will vary with the soil, climatic conditions, and cultivation. Khat belongs to the genus Catha edulis. It is recognized that the genus consists of only one species; however, the plant exhibits extreme polymorphism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Street Names: Khat, Qat, Kat, Chat, Miraa, Quaadka) September 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section KHAT (Street Names: Khat, Qat, Kat, Chat, Miraa, Quaadka) September 2019 Introduction: User Population: Khat, Catha edulis, is a flowering shrub native to East Abuse of khat in the United States is most prevalent among Africa and the Arabian-Peninsula. Khat often refers to the immigrants from Somalia, Ethiopia, and Yemen. Abuse of khat is leaves and young shoot of Catha edulis. It has been widely highest in cities with a substantial population of these immigrants. used since the thirteenth century as a recreational drug by the These cities include Boston (MA), Columbus (OH), Dallas (TX), indigenous people of East Africa, the Arabian Peninsula and Detroit (MI), Kansas City (MO), Los Angeles (CA), Minneapolis (MN), throughout the Middle East. Nashville (TN), New York (NY), and Washington D.C. Licit Uses: Illicit Distribution: There is no accepted medical use in treatment for khat in Individuals of Somali, Ethiopian, and Yemeni descent are the the United States. primary transporters and distributors of khat in the United States. The khat is transported from Somalia into the United States and distributed Chemistry and Pharmacology: in the Midwest, West and Southeast (Nashville, Tennessee) regions Khat contains two central nervous system (CNS) of the United States. According to the National Drug Intelligence stimulants, namely cathinone and cathine. Cathinone (alpha- Center, Somali and Yemen independent dealers are distributing khat aminopriopiophenone), which is considered to be the principal in Ann Arbor, Detroit, Lansing and Ypsilanti, Michigan; Columbus, active stimulant, is structurally similar to d-amphetamine and Ohio; Kansas City, Missouri; and Minneapolis/St.
    [Show full text]
  • Toxicology Times
    TOXICOLOGY (800) 677-7995 TIMES www.sdrl.com A FREE Monthly Newsletter for Substance Abuse and Opioid Treatment Volume 5, Issue 7 Programs from San Diego Reference Laboratory July, 2015 Amphetamines (Part 1) Dr. Joseph E. Graas, Scientific Director most often used in inhalers and does not tite, increased stamina and physical energy, Dr. Edward Moore, Medical Director have the central nervous system activity nor increased sexual response/drive, involuntary any addictive properties. All of the com- body movements, increased perspiration, The term “amphetamines” has come to mean pounds that have the structure of hyperactivity, nausea and increased heart rate. a class of endogenous neurotransmitters that phenylethylamine will have this mixture of d This drug is highly addictive and tolerance stimulate the sympathetic nervous system. and l molecules. In the production of these develops quickly. Withdrawal is an extremely This is a broad class of various substituted drugs they are usually noted as a racemic unpleasant experience. A few street names derivatives of phenylethylamine. This grow- mixture, or specifically, as the d or l com- for the drug are amp, speed, crank, dolls and ing class of structurally related molecules may pound. To properly evaluate this family of crystal. also stimulate the sympathetic nervous sys- compounds known as sympathomimetic tem in many different ways, such as affecting amines, amphetamines or phenylethylamine, Methamphetamine was developed by the the re-release of neurotransmitters or pre- it is best done by describing each member of Japanese in 1919 and used during World War venting the re-uptake of neurotransmitters, the class: amphetamine , methampheta- II to help soldiers stay alert and energize hallucinogens, anorectics, bronchodilators mine , phentermine , phenylpropanola- factory workers.
    [Show full text]
  • Prohibited Chemical Cn Ver4.00.Xlsx
    修订日:2021/7/15 Nitto集团 禁止含有的化学物质 Ver 4.00 分析 备注 物质 化学物质或物质群 阈值 数据 (记载的法律法规只用于对象物质的特定, 例举表 要否 其适用范围不作参考) (不使用保证书中收录的物质) EU REACH法规 AnnexⅩⅦ 未有意添加,且含量不超过1000ppm(不包 石棉类 需要 需要分析的仅限于滑石等可能有石棉混入的 表A 括1000ppm) 矿物原料 ― 部分偶氮染料/颜料(生成特定胺) 未有意添加 EU REACH法规 AnnexⅩⅦ 未有意添加,且镉含量不超过 镉及其化合物 需要 2011/65/EU(EU RoHS2指令) 5ppm(不包括5ppm) 未有意添加,且六价铬含量不超过 六价铬化合物 需要 2011/65/EU(EU RoHS2指令) 100ppm(不包括100ppm) 未有意添加,且铅含量不超过100ppm(不包 铅及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm) 未有意添加,且汞含量不超过100ppm(不包 汞及其化合物 需要 2011/65/EU(EU RoHS2指令) 括100ppm) 未有意添加,且PBB含量不超过100ppm(不 多溴联苯类(PBB类) 需要 2011/65/EU(EU RoHS2指令) 包括100ppm) 未有意添加,且PBDE含量不超过100ppm(不 2011/65/EU(EU RoHS2指令) 多溴联苯醚类(PBDE类) 需要 包括100ppm) 包括十溴联苯醚 蒙特利尔议定书 臭氧层破坏物质 未有意添加 ― 同时禁止在制造工序中使用 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸(2-乙基己基)酯(DEHP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸二正丁酯(DBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸丁基苄酯(BBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 未有意添加,且含量不超过1000ppm(不包 邻苯二甲酸二异丁酯(DIBP) 需要 2011/65/EU(EU RoHS2指令) 括1000ppm) 斯德哥爾摩公約 Annex A 多氯联苯类(PCB类) 未有意添加 ― 第一种特定化学物质(日本 化学物质的审 查及制造等的规制法)(以下简称化审法) 多氯三联苯类(PCT类) 未有意添加 ― EU REACH法规 AnnexⅩⅦ ― 多氯萘(氯原子数大于等于2) 未有意添加 化审法第一种特定化学物质 放射性物质 未有意添加 ― 使用放射性同位素的分析仪器除外 ― 斯德哥爾摩公約 Annex A 短链氯化石蜡(C10-C13) 未有意添加 化审法第一种特定化学物质 EU REACH法规 AnnexⅩⅦ 三丁基氧化锡(TBTO) 未有意添加 ― 化审法第一种特定化学物质 未有意添加,且含量不超过25ppb(不包括 全氟辛酸(PFOA)和其盐类及其PFOA的相关物 POPs公约 Annex A 25ppb)(PFOA相关物质不超过1000ppb) ― 质 EU POPs规则 附属书1 (不包括1000ppb) 未有意添加,且含量不超过25ppb(不包括 全氟乙基磺酸(PFHxS)及其盐类及PFHxS 相关 25ppb)(PFHxS相关物质不超过1000ppb) ― POPs公约 Annex A 物质 (不包括1000ppb) 三取代有机锡化合物 EU REACH法规 AnnexⅩⅦ 未有意添加 ― (包括TBT类、TPT类)(注1)
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]
  • Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3Rd Floor Seacole Building 2
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 18th October 2012 Dear Home Secretary, In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary class drug order was implemented in April 2012. As is now required, the ACMD has followed its initial assessment with a consideration of methoxetamine in the context of the Misuse of Drugs Act 1971; I enclose the report with this letter. The chemical structure of methoxetamine bears a close resemblance to that of both ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well- documented and serious adverse effects following both acute and chronic usage. Users report that the effects of methoxetamine are similar to those of ketamine, however, some users report that the effects are of longer duration.The harmful effects reported include severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant hallucinations. The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation Trust, London in 2011, was of three individuals who presented having self-reported use of methoxetamine. All three presented with a ketamine-like dissociative state, but also had significant stimulant effects with agitation and cardiovascular effects including tachycardia and hypertension. Toxicological screening of serum samples confirmed methoxetamine use in two of the cases.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]